Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05374_nanopub.RA8wBovkpJFrWpnYO96VwjCmRM0i5HiCTyotl_ElUbYeU#assertion>. }
Showing items 1 to 12 of
12
with 100 items per page.
- drugbank:DB05374 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05374 label "CDX-110 [drugbank:DB05374]" assertion.
- drugbank:DB05374 seeAlso DB05374 assertion.
- drugbank:DB05374 description "CDX-110 is developed by Celldex Therapeutics for the treatment of EGFRvIII expressing Glioblastoma Multiforme (GBM). GBM is the most common and aggressive form of brain cancer. CDX-110 is an immunotherapy that targets the tumor-specific growth promoter EGFRvIII." assertion.
- drugbank:DB05374 identifier "drugbank:DB05374" assertion.
- drugbank:DB05374 title "CDX-110" assertion.
- drugbank:DB05374 drugbank_vocabulary:x-cas cas: assertion.
- drugbank:DB05374 drugbank_vocabulary:drugbank-id "DB05374" assertion.
- drugbank:DB05374 bio2rdf_vocabulary:x-identifiers.org DB05374 assertion.
- drugbank:DB05374 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05374" assertion.
- drugbank:DB05374 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05374 bio2rdf_vocabulary:identifier "DB05374" assertion.